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Abstract
Background—Inorganic arsenic is a lung, bladder, and skin carcinogen. One of the major 
sources of exposure to arsenic is through naturally contaminated drinking water. While positive 
associations have been observed between arsenic in drinking water and prostate cancer, few 
studies have explored this association in the United States.
Objectives—To evaluate the association between inorganic arsenic concentrations in community 
water systems and prostate cancer incidence in Illinois using an ecologic study design.
Methods—Illinois Environmental Protection Agency data on arsenic concentrations in drinking 
water from community water systems throughout the state were linked with county-level prostate 
cancer incidence data from 2007 to 2011 from the Illinois State Cancer Registry. Incidence rates 
were indirectly standardized by age to calculate standardized incidence ratios (SIRs) for each 
county. A Poisson regression model was used to model the association between county-level SIRs 
and mean arsenic tertile (0.33 to 0.72, 0.73 to 1.60, and 1.61 to 16.23 ppb), adjusting for potential 
confounders.
Results—For counties with mean arsenic levels in the second tertile, the SIR was 1.05 (95% CI: 
0.96–1.16). For counties with mean arsenic levels in the third tertile, the SIR was 1.10 (95% CI: 
1.03–1.19). There was a significant linear dose-response relationship observed between mean 
arsenic levels and prostate cancer incidence (p for trend = 0.003).
Conclusions—In this ecologic study, counties with higher mean arsenic levels in community 
water systems had significantly higher prostate cancer incidence. Individual-level studies of 
prostate cancer incidence and low-level arsenic exposure are needed.
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1. Introduction
Arsenic is ubiquitous in nature, and is the 20th most common element in the earth’s crust.1 
Arsenic is emitted from volcanic activity and industrial activities, in addition to being 
historically used as a pesticide. For humans, the major source of exposure is through food 
and drinking water.2 In the United States, arsenic is distributed in surface and groundwater at 
varying concentrations, but arsenic in public/community water supplies is not to exceed 10 
parts per billion (ppb) based on the current standard from the Environmental Protection 
Agency (EPA).3 However, concerns remain regarding the carcinogenicity of arsenic in 
drinking water at levels at or below the current guideline.4 In Illinois, the majority of 
community water supplies have arsenic levels below 10 ppb, while private wells are not 
regulated for arsenic concentrations in groundwater.5
The International Agency for Research on Cancer (IARC) has categorized arsenic as a 
“Group 1 Carcinogen,” meaning there is sufficient evidence of carcinogenicity in humans. 
However, the majority of epidemiologic studies focused on the carcinogenicity of arsenic 
have been limited to skin, urinary bladder, and lung cancers.6 There is some evidence of an 
association between arsenic exposure and prostate cancer, the second leading cause of 
cancer death in males in the United States, but this association is not well established for 
low-level arsenic exposure. The majority of existing epidemiologic studies evaluating 
arsenic in relation to prostate cancer have been conducted outside of the United States where 
exposure levels were in excess of 10 ppb.7–14 To date, only two studies on arsenic and 
prostate cancer have been conducted in the United States (Table 1).15,16 Garcia-Esquinas et 
al. (2013) found a 4-fold increase in the hazard of prostate cancer mortality (hazard ratio: 
4.58, 95% CI: 1.31–16.6) when comparing those in the highest tertile of total urinary arsenic 
(>13.32 µg/g creatinine) to those in the lowest tertile (<6.91 µg/g creatinine) among 
American Indians in Arizona, Oklahoma, North Dakota, and South Dakota, in what is to 
date the only prospective cohort study of low-dose arsenic exposure in the United States. 
Lewis et al. (1999) found elevated mortality from prostate cancer among men exposed to 
medium (1,000–4,999 ppb-years) and high levels (≥5,000 ppb-years) of cumulative arsenic 
exposure based on ecologic measurements of arsenic in community water supplies in Utah. 
It has been suggested that arsenic can impact prostate cancer cell progression through 
androgen-independence, which is often associated with advanced and lethal prostate cancers 
that are difficult to treat.17, 18 Other research has suggested that arsenic exposure through 
drinking water inhibits DNA repair processes as part of its carcinogenic mechanism of 
action.19
Given the limited existing epidemiologic studies examining the association between low-
level arsenic exposure and prostate cancer, we sought to examine the association between 
inorganic arsenic concentration in community water supplies and prostate cancer incidence 
in Illinois using an ecologic study design.
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The county-level concentration of arsenic in finished drinking water (water that has been 
treated and is ready for distribution and consumption by the public), provided by community 
water systems (CWSs) between 2000 and 2006, was the main exposure of interest. Prostate 
cancer incidence data from the Illinois State Cancer Registry for 2007–2011 aggregated at 
the county-level were merged with county-level population and demographic data from the 
National Cancer Institute Surveillance, Epidemiology, and End Results (SEER) program. As 
such, an ecological analysis was conducted at the county-level. This study was approved by 
the University of Illinois at Chicago Institutional Review Board.
2.1 Water Data
Arsenic levels in finished drinking water provided by community water systems (CWSs) 
were obtained from Illinois Safe Drinking Water Information System (SDWIS) for the 
period January 1, 2000 to December 31, 2006. CWSs are public water systems that supply 
water for human consumption to the same population-year round through at least 15 service 
connections or to at least 25 people.20 The Arsenic and Clarifications to Compliance and 
New Source Monitoring Rule 66 FR 6976, which was finalized in January 2001, required 
CWSs using groundwater to take one sample between 1999–2001, 2002–2004, and 2005–
2006; annual measurements were required for CWSs using surface water.
The most frequently reported limits of detection (for samples identified below the detection 
limit) were 0.5 ppb (n=1,509 samples) and 1 ppb (n=1,401 samples), and ranged from 0–50 
ppb. For samples below the limit of detection, the value imputed was ½ the limit of 
detection. If the limit of detection was reported as zero, then 0.25 ppb was imputed (n=6 
samples). Overall, 50.9% of samples were indicated to be below the limit of detection.
CWSs were linked to counties based on the CWS address. County-level monthly average 
arsenic levels were calculated by averaging the arsenic levels in finished water for all CWSs 
in each county. The exposure metric was the county-level average arsenic level over the 
period 2000 through 2006, which was the average of the county-level monthly average 
arsenic levels. No arsenic data were available for 2 of the 102 counties in Illinois and were 
excluded from the analysis. Data may not have been available for these counties because 
they were served by CWSs with addresses in other counties, or lack of arsenic measurement.
Since some households in counties may be served by private wells, we accounted for the 
proportion of residents in a county who reported domestic private well use to the United 
States Geological Survey in 2000 rather than use of CWSs, which was included as a 
covariate in our analyses.21 While arsenic may also be present in private well water, arsenic 
concentrations were not available for these water sources since there is no systematic 
monitoring of arsenic in private wells in Illinois.
2.2 Cancer Data
The Illinois State Cancer Registry (ISCR) provided data for all incident cases of prostate 
cancer between 2007 and 2011 among adults (aged ≥ 15 years) residing in Illinois at the 
time of diagnosis. Age-specific (crude) prostate cancer incidence rates from 2007–2011 for 
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the whole state of Illinois were calculated in order to indirectly standardize the county-level 
incidence rates by age. Standardized incidence ratios (SIRs) were calculated for each county 
by dividing the number of observed cases by expected cases. As such, a value of greater than 
1 indicates that more cancer cases were observed in that county than expected based on the 
age demographics of males in that county, and a value of less than 1 indicates fewer cancer 
cases were observed in that county than expected.
2.3 County Population and Demographic Data
Population and demographic data for 102 Illinois counties were obtained from SEER, 
courtesy of the Illinois State Cancer Registry. Population estimates incorporated intercensal 
years (for 2007 to 2009) and Vintage 2012 (for 2010 to 2011). More information on the 
population estimates and associated methodology can be found elsewhere.22 Supplementary 
data on the percent of individuals in the county living under the federal poverty level, used 
as a metric for socioeconomic status, were obtained from the 2010 Small Area Income and 
Poverty Estimates (SAIPE) program at the U.S. Census Bureau.23
2.4 Geographic Data
Choropleth maps to depict mean arsenic level by county and standardized incidence ratios 
by county were created using ArcGIS 10 (ESRI, Redlands, CA). County shapefiles were 
obtained from the U.S. Census Bureau’s 2010 TIGER/Line files.24
2.5 Statistical Analysis
A Poisson regression model with robust standard errors was constructed under the 
assumption that the number of observed incident cancer cases for each county had a Poisson 
distribution, where the expected number of cases for that county was based on the county’s 
age demographics. The natural log of the expected number of cases was included in the 
model as an offset term. The explanatory variables were arsenic tertiles, with the lowest 
tertile serving as the reference category. The average level of arsenic in CWSs for each 
county from 2000 to 2006 was categorized into tertiles, with the first tertile representing a 
mean arsenic level between 0.33 and 0.72 parts per billion (ppb), the second tertile 
representing a mean arsenic level between 0.73 and 1.60 ppb, and the third tertile 
representing a mean arsenic level between 1.61 and 16.23 ppb. Arsenic tertiles were also 
modeled as an ordinal variable to calculate the p-value for trend. Since there was evidence of 
linear trend, models were also run using arsenic as a continuous exposure variable as an 
average per 10 ppb increase. In addition to crude regression models, adjusted model 1 
included the percentage of black male residents and the percentage of other race male 
residents in the county. Adjusted model 2 included the covariates in adjusted model 1, with 
the addition of the percentage of the county population living below the federal poverty line. 
Adjusted model 3 included all covariates in adjusted model 2, in addition to the percentage 
of private well users in the county. Covariates were all modeled as continuous variables.
Robust standard errors for parameter estimates were used to control for mild violations of 
the Poisson distribution assumption that the mean equals the variance.25 The model residuals 
were tested for spatial autocorrelation by calculating a Global Moran’s I statistic. Poisson 
regression models that included a random effect for each county with a spatial covariance 
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structure based on the latitude and longitude of each county’s centroid were also performed 
to control for spatial autocorrelation. Since prostate cancer is rare among younger males and 
may be related to misclassification or different etiology, we performed a sensitivity analysis 
excluding males <45 years old. All statistical analyses were performed using SAS version 
9.3 (Cary, NC).
3. Results
Between 2007 and 2011, there were 45,595 incident prostate cancer cases among 4,936,634 
males ≥15 years old in the state of Illinois (Table 2). The majority of cases occurred among 
men between the ages of 55 and 74 years old. Mean arsenic levels and prostate cancer SIRs 
by county are presented in Figures 1 and 2. The distributions of county-level covariates 
across arsenic tertiles are provided in Table 3. Both the crude and adjusted Poisson 
regression results suggested prostate cancer incidence greater than expected among counties 
with elevated arsenic levels (Table 4). For counties with mean arsenic levels in the second 
tertile, the SIR was 1.05 (95% CI: 0.96–1.16) when adjusted for private well use, racial 
demographics, and socioeconomic status. For counties with mean arsenic levels in the third 
tertile, the SIR was 1.10 (95% CI: 1.03–1.19) accounting for covariates. There was a 
significant linear dose-response relationship observed between mean arsenic levels and 
prostate cancer incidence (p for trend = 0.003). Results when modeling arsenic as a 
continuous variable showed that a 10 ppb increase in mean arsenic levels was associated 
with a 12% increase in the standardized incidence ratio (95% CI: 1.04–1.20) for prostate 
cancer when adjusting for confounders.
Residuals from the standard Poisson regression model were significantly positively spatially 
autocorrelated (Moran’s I statistic: 0.19, p-value: <0.001). The results from the spatial 
autocorrelation model were similar to the standard Poisson regression model (Table 5). For 
counties with mean arsenic levels in the second tertile, the SIR was 1.05 (95% CI: 0.98–
1.13) when adjusted for private well use, racial demographics, socioeconomic status, and 
spatial autocorrelation. For counties with mean arsenic levels in the third tertile, the SIR was 
1.08 (95% CI: 1.00–1.15) accounting for covariates and spatial autocorrelation. Again, there 
was a significant linear dose-response relationship observed (p for trend = 0.039). When 
analyzed continuously, an average 10 ppb increase in arsenic levels was associated with an 
8% increase in the standardized incidence ratio (95% CI: 1.01–1.16) of prostate cancer after 
adjusting for confounders and controlling for spatial autocorrelation. We found no 
appreciable differences in model estimates when restricting the analyses to males older than 
45 years (data not shown).
4. Discussion
The majority of counties in Illinois had mean arsenic levels in the CWSs below the current 
U.S. EPA standard of 10 ppb, and all counties had mean arsenic levels in CWSs below the 
prior EPA standard of 50 ppb which was in place until 2006.3 Prostate cancer incidence was 
significantly higher in counties with higher mean CWS arsenic levels, even after controlling 
for known confounding factors and spatial autocorrelation.
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While skin, lung, and bladder cancers are well-established arsenic-related cancers, the link 
with prostate cancer is less known. Biologically, it has been suggested that arsenic exposure 
increases the risk of prostate cancer through epigenetic mechanisms that increase cell growth 
and cell survival while decreasing apoptosis. In the prostate specifically, studies of human 
prostate epithelial cells in culture have demonstrated that low level exposure to inorganic 
arsenic induces malignant transformations that involve increases in matrix 
metalloproteinase-9 secretion,26 inhibition of apoptosis,27 aberrant genomic DNA 
methylation,28 and K-ras oncogene activation and overexpression29, 30 among others.17 
Additionally, inorganic arsenic exposure stimulates androgen independence, which is often 
associated with advanced stages of prostate cancer and a poor prognosis due to resistance to 
certain types of treatment.18,31, 32 Recent research suggests that arsenic exposure can 
transform human prostate epithelial stem/progenitor cells into cancer stem-like cells that 
result in highly pleomorphic and aggressive tumors, and that these arsenic-transformed 
malignant prostate epithelial cells can then recruit nearby non-contiguous normal stem cells 
into a cancer phenotype.33, 34
Since this study was performed on county-level data, individual-level inferences are limited. 
It is unknown whether prostate cancer cases in these Illinois counties were exposed to higher 
concentrations of arsenic than non-cases. Therefore, individual-level studies of prostate 
cancer incidence and arsenic exposure are needed to confirm the associations observed in 
this analysis.
As an ecologic study, it is possible that confounding may have biased our results. We 
adjusted for age by standardizing, and further controlled for county-level covariates 
including race/ethnicity, socioeconomic status, and private well use in the regression models. 
Family history, an established risk factor of prostate cancer, was not accounted for due to 
absence of an appropriate data source for this information. It is possible that observed 
associations may be confounded by family history of prostate cancer if family history is 
related to reduced family mobility and thus ingestion of arsenic through the CWS. The 
findings of the current study require replication in other observational studies.
Another limitation of this analysis is the representativeness of CWS data. Community water 
systems are one of three types of public water systems.20 Other types of public water 
systems include non-transient non-community water systems, which regularly provide water 
to at least 25 of the same people for at least 6 months per year, and transient non-community 
water systems, which provide water to places where people do not remain for long periods 
of time.20 While CWS data are likely to reflect the major source of residential exposure to 
arsenic through drinking water, non-transient water sources like schools, hospitals, office 
buildings, and transient sources like campgrounds were not included in this analysis. The 
absence of arsenic exposure through private household well water sources is also a 
limitation. Private wells in Illinois are not regulated and therefore data on arsenic 
concentrations in these wells is not available. We included the percent of private well users 
as a covariate in our regression models, but this may not adequately address the lack of well 
arsenic data. Other limitations include prostate cancer latency and exposure 
misclassification. With arsenic exposure data from 2000 to 2006 and prostate cancer 
incidence data from 2007 to 2011, our data allow for a latency period up to 11 years. The 
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average estimated latency period for prostate cancer is approximately 7 to 12 years, so some 
cases associated with arsenic may have been missed.35 Furthermore, as an ecologic study we 
did not have individual data on residential history, which may have resulted in 
misclassification bias of arsenic exposure through the CWSs.
5. Conclusions
This is one of few studies to analyze low-level arsenic exposure through drinking water and 
prostate cancer. The significant association observed between counties with higher arsenic 
levels in community water systems and prostate cancer incidence greater than expected 
warrants further research. Future studies should examine this association using individual-
level data including individual arsenic exposure assessments.
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• Arsenic is a known carcinogen, but it is unclear if it causes prostate cancer.
• We used data on arsenic levels in community water systems in Illinois.
• County-level mean arsenic was associated with increased prostate cancer 
incidence.
• There was a significant linear dose-response.
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Mean Arsenic Values (ppb) by County from 2000 to 2006
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Prostate Cancer Standardized Incidence Ratios by County for 2007 to 2011
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Table 2








  15 to 34 years 4 (0.01) 1,804,545 (36.55)
  35 to 44 years 285 (0.63) 869,273 (17.61)
  45 to 54 years 4,753 (10.42) 910,508 (18.44)
  55 to 64 years 15,027 (32.96) 688,680 (13.95)
  65 to 74 years 16,250 (35.64) 378,657 (7.67)
  75 years and older 9,276 (20.34) 284,971 (5.77)
*
Population data were averaged across the 5-year period from 2007–2011 based on intercensal data17
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Table 3










Percent of White Males 91.10 76.23 89.50
Percent of Black Males 7.43 16.93 7.22
Percent of Other Race Males 1.47 6.84 3.28
Percent of Individuals Living in Poverty 14.62 14.43 11.75
Percent of Private Well Users 31.90 39.77 31.07
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Table 4
Standard Poisson Regression Results (Crude and Adjusted)
Model Exposure Variable SIR (95% CI) p-value p for trend
Crude Arsenic tertiles 0.181
0.33 to 0.72 ppb 1.00 (reference)
0.73 to 1.60 ppb 1.17 (1.08–1.26) <0.001
1.61 to 16.23 ppb 1.13 (1.05–1.21) 0.001
Adjusted 1 Arsenic tertiles 0.001
0.33 to 0.72 ppb 1.00 (reference)
0.73 to 1.60 ppb 1.07 (0.98–1.17) 0.146
1.61 to 16.23 ppb 1.12 (1.05–1.20) 0.001
Adjusted 2 Arsenic tertiles 0.004
0.33 to 0.72 ppb 1.00 (reference)
0.73 to 1.60 ppb 1.05 (0.96–1.15) 0.299
1.61 to 16.23 ppb 1.10 (1.02–1.18) 0.011
Adjusted 3 Arsenic tertiles 0.003
0.33 to 0.72 ppb 1.00 (reference)
0.73 to 1.60 ppb 1.05 (0.96–1.16) 0.264
1.61 to 16.23 ppb 1.10 (1.03–1.19) 0.008
Crude Arsenic (per 10 ppb) 1.01 (0.93–1.10) 0.794
Adjusted 1 Arsenic (per 10 ppb) 1.06 (0.96–1.17) 0.233
Adjusted 2 Arsenic (per 10 ppb) 1.10 (1.02–1.19) 0.013
Adjusted 3 Arsenic (per 10 ppb) 1.12 (1.04–1.20) 0.004
1
Adjusted for the percentage of black male residents, and the percentage of other race male residents
2
Adjusted for the percentage of black male residents, the percentage of other race male residents, and the percentage of residents living below the 
federal poverty line
3
Adjusted for the percentage of black male residents, the percentage of other race male residents, the percentage of residents living below the 
federal poverty line, and the percentage of residents reporting private well use
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Table 5
Spatial Autocorrelation Poisson Regression Results (Crude and Adjusted)
Model Exposure Variable SIR (95% CI) p-value p for trend
Crude Arsenic tertiles 0.013
0.33 to 0.72 ppb 1.00 (reference)
0.73 to 1.60 ppb 1.08 (1.00–1.16) 0.036
1.61 to 16.23 ppb 1.09 (1.02–1.17) 0.011
Adjusted 1 Arsenic tertiles 0.021
0.33 to 0.72 ppb 1.00 (reference)
0.73 to 1.60 ppb 1.07 (1.00–1.15) 0.061
1.61 to 16.23 ppb 1.10 (1.02–1.17) 0.010
Adjusted 2 Arsenic tertiles 0.037
0.33 to 0.72 ppb 1.00 (reference)
0.73 to 1.60 ppb 1.05 (0.97–1.13) 0.216
1.61 to 16.23 ppb 1.08 (1.01–1.15) 0.037
Adjusted 3 Arsenic tertiles 0.039
0.33 to 0.72 ppb 1.00 (reference)
0.73 to 1.60 ppb 1.05 (0.98–1.13) 0.173
1.61 to 16.23 ppb 1.08 (1.00–1.15) 0.037
Crude Arsenic (per 10 ppb) 1.07 (1.00–1.15) 0.066
Adjusted 1 Arsenic (per 10 ppb) 1.07 (0.99–1.15) 0.070
Adjusted 2 Arsenic (per 10 ppb) 1.08 (1.01–1.16) 0.032
Adjusted 3 Arsenic (per 10 ppb) 1.08 (1.01–1.16) 0.024
1
Adjusted for the percentage of black male residents, and the percentage of other race male residents
2
Adjusted for the percentage of black male residents, the percentage of other race male residents, and the percentage of residents living below the 
federal poverty line
3
Adjusted for the percentage of black male residents, the percentage of other race male residents, the percentage of residents living below the 
federal poverty line, and the percentage of residents reporting private well use
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